Comparison of Adductor Pollicis and Abductor Digiti Minimi Muscles (Thumb Vs. Fifth Digit) As Sites for Neuromuscular Monitoring with Electromyography

Launched by TAMAS VEGH, MD · Nov 13, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how well a device called TetraGraph works for monitoring muscle function during surgery. Specifically, it will compare two muscles in the arm—the adductor pollicis, which helps move the thumb, and the abductor digiti minimi, which helps move the little finger. The goal is to see how quickly patients recover from a muscle relaxant called rocuronium after surgery, especially when another medication, sugammadex, is used to help with recovery.

To participate in this study, patients need to be at least 18 years old and willing to give their consent. They should be scheduled for elective surgeries that require muscle relaxants. However, those with certain medical conditions—like severe nerve injuries, neuromuscular diseases, or significant organ problems—may not be eligible. Participants can expect to receive careful monitoring of their muscle function during and after surgery, helping doctors understand the best ways to ensure safe recovery from anesthesia.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> or = 18 years old
• • Patients willing to participate and provide an informed consent
• • Patients undergoing elective surgical procedures that require use of NMBA agents (rocuronium) administered intraoperatively.
• Exclusion Criteria:
• • Patients with disorders, such as stroke, carpal tunnel syndrome, broken wrist with nerve damage, Dupuytren contracture, or any similar wrist injury.
• • Patients with systemic neuromuscular diseases such as myasthenia gravis.
• • Patients with significant organ dysfunction that can significantly affect pharmacokinetics of neuromuscular blocking and reversal agents, i.e., severe renal impairment or end-stage liver disease.
• • Patients having surgery that would involve prepping the arm into the sterile field.
• • Patients receiving a rapid sequence induction.
• • Patients allergic to rocuronium or sugammadex.